Drug chiefs in Senate strike conciliatory note over prices

27 February 2019
congress_senate_house_hearing_committee_enquiry_big

In Washington DC on Tuesday, the chief executives of half a dozen leading drugmakers defended the industry’s drug pricing rationale and shifted the blame for high prices onto the sector’s intermediaries.

AbbVie CEO Richard Gonzalez was challenged over a more than-doubling of the price of anti-TNF super-blockbuster Humira (adalimumab) in the sunset years of its patent estate.

Defending the approach, he noted the therapy “plays a very important role in AbbVie's overall funding of R&D,” while senators acknowledged a balance between affordability and the need to pay for innovation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical